Jednoczasowa obustronna iniekcja ranibizumabu (Lucentis) do ciała szklistego w leczeniu ratunkowym postępującej retinopatii wcześniaków – doniesienie wstępne
Concomitant Bilateral Intravitreal Ranibizumab (Lucentis) Injections in Salvage Therapy in Retinopathy of Prematurity Treatment – Preliminary Report
Małgorzata Seroczyńska, Beata Kocyła-Karczmarewicz, Mirosława Grałek, Wojciech Hautz, Krystyna Kanigowska
Klinika Okulistyki Instytutu „Pomnik – Centrum Zdrowia Dziecka” w Warszawie
P.o. kierownika: dr n. med. Wojciech Hautz
Summary: To present the course of treatment of prematurely born infants suffering from aggressive stage of ROP treated with intravitreal ranibizumab injections after ineffective laser photocoagulation.
Purpose: Efficacy of intravitreal ranibizumab injections in Retinopathy of Prematurity treatment, in own material.
Material and Methods: 9 children (18 eyes) born in 23–29 week of pregnancy, 6–8 weeks old, who were treated with concomitant bilateral intravitreal 0.25 mg ranibizumab injections.
Results: 16 eyes were treated successfully with only one injection. One eye failed to achieve improvement, in one eye partial improvement was obtained. There have been no significant complications, local nor general.
Conclusions: The presented material of ranibizumab injections to the vitreous body was safe and effective in the treatment of severe ROP form resistant to conventional diode laser treatment in extremely immature, premature infants with inherited susceptibility to a disease.
Functional assessment of patients is not complete due to the age at the moment of examination, however, the results suggest that there is no serious damage to the retinal function resulting from the ranibizumab application. The anatomic results of treatment do not determine functional results in this group of patients to the same extent as in more mature and less susceptible to a disease premature infants, as some babies with beneficial effect of treatment of the retina may see poorly because of damages to their nervous systems.
Słowa kluczowe: terapia anty-VEGF, ranibizumab, retinopatia wcześniaków, leczenie ratujące.
Keywords: anti-VEGF therapy, ranibizumab, retinopathy of prematurity, salvage therapy.